{
  "clinical_study": {
    "title": "A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).",
    "nct_identifier": "NCT05975905",
    "indication": "Pulmonary Arterial Hypertension",
    "intervention": "Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks",
    "study_arms": {
      "intervention": 3,
      "placebo": 1
    },
    "number_of_participants": 113,
    "average_age": null,
    "age_range": [
      "18 Years",
      "N/A"
    ],
    "interventional_drug": [
      {
        "name": "Dose A KER-012",
        "dose": null,
        "frequency": "Q4W",
        "formulation": null
      },
      {
        "name": "Dose B KER-012",
        "dose": null,
        "frequency": "Q4W",
        "formulation": null
      },
      {
        "name": "Dose C KER-012",
        "dose": null,
        "frequency": "Q4W",
        "formulation": null
      },
      {
        "name": "KER-012",
        "dose": "Dose B",
        "frequency": "Q4W",
        "formulation": "SC"
      }
    ],
    "endpoints": [
      "Change from Baseline in PVR (Pulmonary Vascular Resistance)",
      "Change from Baseline in the 6MWD",
      "Incidence of treatment-emergent adverse events (TEAEs)",
      "Number of treatment-related TEAEs",
      "Number of discontinuations due to TEAEs",
      "Change from baseline in Systolic and Diastolic Blood Pressure",
      "Change from baseline in QTcF intervals",
      "Incidence of Antidrug Antibodies (ADA)",
      "Evaluate the changes from baseline in the concentration of the PAH biomarker, NT-proBNP in blood samples",
      "Evaluate the effect of KER-012 on pulmonary hemodynamics compared to Placebo in participants on background PAH therapy- mPAP",
      "Evaluate the effect of KER-012 on pulmonary hemodynamics compared to Placebo in participants on background PAH therapy- CO",
      "Evaluate the effect of KER-012 on pulmonary hemodynamics compared to Placebo in participants on background PAH therapy- PAWP",
      "Evaluate improvement in functional assessment of KER-012 compared to Placebo in participants on background PAH therapy",
      "Number of participants who experienced events indicative of clinical worsening of pulmonary arterial hypertension (PAH)",
      "Population PK predicted maximum concentration (Cmax) of KER-012",
      "Population PK predicted Area under concentration curve (AUC) of KER-012",
      "Evaluate improvement in risk stratifications of KER-012 in participants on background PAH therapy"
    ],
    "baseline_characteristics": []
  },
  "endpoints": [
    {
      "name": "Change from Baseline in PVR (Pulmonary Vascular Resistance)",
      "description": "Evaluate the effect of KER-012 on pulmonary hemodynamics compared to Placebo in participants on background pulmonary arterial hypertension (PAH) therapy",
      "timepoint": "Baseline and Week 24",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Change from Baseline in the 6MWD",
      "description": "Evaluate the effect of KER-012 on exercise capacity compared to Placebo in participants on background PAH therapy",
      "timepoint": "Through week 24 (primary treatment period) and Through week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Incidence of treatment-emergent adverse events (TEAEs)",
      "description": "A TEAE is any untoward medical occurrence in a study participant occurring after the initiation of a study treatment that does not necessarily have to have a causal relationship with this treatment. A TEAE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.",
      "timepoint": "Through week 24 (primary treatment period) and Through week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Number of treatment-related TEAEs",
      "description": "A treatment-related TEAE is any untoward medical occurrence in a study participant occurring after the initiation of a study treatment that has a causal relationship with this treatment.",
      "timepoint": "Through week 24 (primary treatment period) and Through week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Number of discontinuations due to TEAEs",
      "description": "A treatment-related TEAE is any untoward medical occurrence in a study participant occurring after the initiation of a study treatment that has a causal relationship with this treatment. A TEAE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.",
      "timepoint": "Through week 24 (primary treatment period) and Through week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Change from baseline in Systolic and Diastolic Blood Pressure",
      "description": "Systolic and Diastolic blood pressure measured in mmHg",
      "timepoint": "Through week 24 (primary treatment period) and Through week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Change from baseline in QTcF intervals",
      "description": "QTcF intervals measured in msec via ECGs",
      "timepoint": "Through week 24 (primary treatment period) and Through week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Incidence of Antidrug Antibodies (ADA)",
      "description": "The amount of ADA measured in serum",
      "timepoint": "Through week 24 (primary treatment period) and Through week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Evaluate the changes from baseline in the concentration of the PAH biomarker, NT-proBNP in blood samples",
      "description": "Change from Baseline in NT-proBNP by visit",
      "timepoint": "Up to week 24 (primary treatment period) and up to Week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Evaluate the effect of KER-012 on pulmonary hemodynamics compared to Placebo in participants on background PAH therapy- mPAP",
      "description": "Change from Baseline in mean pulmonary artery pressure (mPAP)",
      "timepoint": "Up to week 24 (primary treatment period) and up to Week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Evaluate the effect of KER-012 on pulmonary hemodynamics compared to Placebo in participants on background PAH therapy- CO",
      "description": "Change from Baseline in cardiac output (CO)",
      "timepoint": "Up to week 24 (primary treatment period) and up to Week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Evaluate the effect of KER-012 on pulmonary hemodynamics compared to Placebo in participants on background PAH therapy- PAWP",
      "description": "Change from Baseline in pulmonary artery wedge pressure (PAWP)",
      "timepoint": "Up to week 24 (primary treatment period) and up to Week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Evaluate improvement in functional assessment of KER-012 compared to Placebo in participants on background PAH therapy",
      "description": "Proportion of participants who achieved improvement from Baseline in NYHA FC/WHO by visit",
      "timepoint": "Up to week 24 (primary treatment period) and up to Week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Number of participants who experienced events indicative of clinical worsening of pulmonary arterial hypertension (PAH)",
      "description": "Events that indicate clinical worsening of PAH include death, non-elective PAH-related hospitalization and/or right heart failure inclusive of lung or heart/lung transplant, or atrial septostomy, need to initiate an approved PAH SOC rescue therapy, or functional deterioration (worsened WHO Functional Class AND 15% decrease in 6MWD).",
      "timepoint": "Up to week 24 (primary treatment period) and up to Week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Population PK predicted maximum concentration (Cmax) of KER-012",
      "description": "Cmax is a measure of the maximum concentration of a drug in the serum after the dose is given.",
      "timepoint": "Through week 24 (primary treatment period) and Through week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Population PK predicted Area under concentration curve (AUC) of KER-012",
      "description": "AUC is a measure of the area under the serum concentration curve after dose is given.",
      "timepoint": "Through week 24 (primary treatment period) and Through week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Evaluate improvement in risk stratifications of KER-012 in participants on background PAH therapy",
      "description": "Proportion of participants who achieve improvement/or maintain low risk in ESC/ ERC 4-strata risk category assessment",
      "timepoint": "Up to week 24 (primary treatment period) and up to Week 96 (extension period)",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    }
  ],
  "baseline_measures": []
}